Tagged With "treatment"

Blog Post

FDA Approves Cinqair to Treat Severe Asthma

AAFA Community Services ·
FDA News Release FDA approves Cinqair to treat severe asthma For Immediate Release March 23, 2016 Inquiries Media Andrea Fischer 301-796-0393 Consumers 888-INFO-FDA Release The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current...
Blog Post

Xolair Approved for Children with Asthma Triggered by Allergens

AAFA Community Services ·
There is a new drug available for children with uncontrolled asthma caused by airborne allergens. Xolair is already approved for people, ages 12 and older, with moderate to severe asthma. It belongs to a class of drugs called biologics. It is given in a doctor’s office by injection. The FDA recently approved it for children between ages 6 and 11 whose asthma is not controlled with other long-term medications . Approval makes Xolair the only biologic for children with uncontrolled allergic...
Blog Post

FDA Approves Symbicort to Treat Asthma In Children Ages 6-12

AAFA Community Services ·
AstraZeneca announced that the US Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years.
Blog Post

FDA Approves Two New Asthma Inhalers

AAFA Community Services ·
[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.
×
×
×
×